keyword
Keywords Triple negative breast cancer ...

Triple negative breast cancer and metformin

https://read.qxmd.com/read/38464382/efficacy-of-metformin-and-electrical-pulses-in-breast-cancer-mda-mb-231-cells
#1
JOURNAL ARTICLE
Praveen Sahu, Ignacio G Camarillo, Raji Sundararajan
AIM: Triple-negative breast cancer (TNBC) is a very aggressive subset of breast cancer, with limited treatment options, due to the lack of three commonly targeted receptors, which merits the need for novel treatments for TNBC. Towards this need, the use of metformin (Met), the most widely used type-2 diabetes drug worldwide, was explored as a repurposed anticancer agent. Cancer being a metabolic disease, the modulation of two crucial metabolites, glucose, and reactive oxygen species (ROS), is studied in MDA-MB-231 TNBC cells, using Met in the presence of electrical pulses (EP) to enhance the drug efficacy...
2024: Exploration of targeted anti-tumor therapy
https://read.qxmd.com/read/38459750/design-optimization-characterization-and-in%C3%A2-vitro-evaluation-of-metformin-loaded-liposomes-for-triple-negative-breast-cancer-treatment
#2
JOURNAL ARTICLE
Daiva Vozgirdaite, Katel Hervé-Aubert, Rustem Uzbekov, Igor Chourpa, Emilie Allard-Vannier
Recently, metformin (Met) has shown to have antineoplastic properties in cancer treatment by improving hypoxic tumor conditions, and causing reduction in the synthesis of biomolecules, which are vital for cancer growth. However, as an orally administered drug, Met has low bioavailability and rapid renal clearance. Thus, the goal of this study was to vectorize Met inside liposomes in the context of triple negative breast cancer (TNBC), which currently lacks treatment options when compared to other types of breast cancer...
March 8, 2024: Journal of Liposome Research
https://read.qxmd.com/read/38432130/everolimus-decreases-u-13-c-glucose-utilization-by-pyruvate-carboxylase-in-breast-cancer-cells-in-vitro-and-in-vivo
#3
JOURNAL ARTICLE
Gerke Ariaans, Jiske F Tiersma, Bernardus Evers, Albert Gerding, Stijn J H Waaijer, Remco A Koster, Daan J Touw, Barbara M Bakker, Dirk-Jan Reijngoud, Steven de Jong, Mathilde Jalving
Reprogrammed metabolism is a hallmark of cancer, but notoriously difficult to target due to metabolic plasticity, especially in response to single metabolic interventions. Combining mTOR inhibitor everolimus and mitochondrial complex 1 inhibitor metformin results in metabolic synergy in in vitro models of triple-negative breast cancer. Here, we investigated whether the effect of this drug combination on tumor size is reflected in changes in tumor metabolism using [U-13 C]glucose labeling in an MDA-MB-231 triple negative breast cancer xenograft model...
March 2, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38196628/the-combined-treatment-with-ketogenic-diet-and-metformin-slows-tumor-growth-in-two-mouse-models-of-triple-negative-breast-cancer
#4
Karen Schmidt, Amber Thatcher, Albert Grobe, Linda Hicks, Haiwei Gu, Dorothy D Sears, Lesley G Ellies, Leonid Kalachev, Eugene Kroll
BACKGROUND Many tumors contain hypoxic microenvironments caused by inefficient tumor vascularization. Hypoxic tumors have been shown to resist conventional cancer therapies. Hypoxic cancer cells rely on glucose to meet their energetic and anabolic needs to fuel uncontrolled proliferation and metastasis. This glucose dependency is linked to a metabolic shift in response to hypoxic conditions. METHODS To leverage the glucose dependency of hypoxic tumor cells, we assessed the effects of a controlled reduction in systemic glucose by combining dietary carbohydrate restriction, using a ketogenic diet, with gluconeogenesis inhibition, using metformin, on two mouse models of triple-negative breast cancer (TNBC)...
December 20, 2023: Research Square
https://read.qxmd.com/read/38167105/enhancement-of-targeted-therapy-in-combination-with-metformin-on-human-breast-cancer-cell-lines
#5
JOURNAL ARTICLE
Ghazal Mahmoudi, Yahya Ehteshaminia, Parviz Kokhaei, Seyedeh Farzaneh Jalali, Farhad Jadidi-Niaragh, Abdol Sattar Pagheh, Seyed Ehsan Enderami, Saeid Abedian Kenari, Hadi Hassannia
BACKGROUND: Breast cancer remains a primary global health concern due to its limited treatment options, frequent disease recurrence, and high rates of morbidity and mortality. Thereby, there is a need for more effective treatment approaches. The proposal suggests that the combination of targeted therapy with other antitumoral agents could potentially address drug resistance. In this study, we examined the antitumoral effect of combining metformin, an antidiabetic drug, with targeted therapies, including tamoxifen for estrogen receptor-positive (MCF-7), trastuzumab for HER2-positive (SKBR-3), and antibody against ROR1 receptor for triple-negative breast cancer (MDA-MB-231)...
January 2, 2024: Cell Communication and Signaling: CCS
https://read.qxmd.com/read/38139780/md-simulations-to-calculate-nmr-relaxation-parameters-of-vanadium-iv-complexes-a-promising-diagnostic-tool-for-cancer-and-alzheimer-s-disease
#6
JOURNAL ARTICLE
Rodrigo Mancini Santos, Camila Assis Tavares, Taináh Martins Resende Santos, Hassan Rasouli, Teodorico Castro Ramalho
Early phase diagnosis of human diseases has still been a challenge in the medicinal field, and one of the efficient non-invasive techniques that is vastly used for this purpose is magnetic resonance imaging (MRI). MRI is able to detect a wide range of diseases and conditions, including nervous system disorders and cancer, and uses the principles of NMR relaxation to generate detailed internal images of the body. For such investigation, different metal complexes have been studied as potential MRI contrast agents...
November 27, 2023: Pharmaceuticals
https://read.qxmd.com/read/38116319/low-glucose-availability-potentiates-the-effects-of-metformin-on-model-t-cell-activation-and-exhaustion-markers-in-vitro
#7
JOURNAL ARTICLE
Jernej Repas, Lea Peternel, Harald Sourij, Mojca Pavlin
Modulation of immune cell metabolism is one of promising strategies to improve cancer immunotherapies. Metformin is an anti-diabetic drug with potential anti-cancer effects, ranging from normalization of blood glucose and insulin levels, direct anti-proliferative effects on cancer cells to emerging immunomodulatory effects on anti-tumor immunity. Metformin can reduce tumor hypoxia and PD-L1 expression, as well as normalize or improve T cell function and potentiate the effect of immune checkpoint inhibitors, making it a promising adjuvant to immunotherapy of tumors with poor response such as triple negative breast cancer (TNBC)...
2023: Frontiers in Endocrinology
https://read.qxmd.com/read/37762429/evaluating-18-f-fdg-and-18-f-flt-radiotracers-as-biomarkers-of-response-for-combined-therapy-outcome-in-triple-negative-and-estrogen-receptor-positive-breast-cancer-models
#8
JOURNAL ARTICLE
Paolo Rainone, Silvia Valtorta, Chiara Villa, Sergio Todde, Massimiliano Cadamuro, Gloria Bertoli, Donatella Conconi, Marialuisa Lavitrano, Rosa Maria Moresco
Breast cancer (BC) is the most frequent cancer and the second leading cause of death in women. A typical feature of BC cells is the metabolic shift toward increased glycolysis, which has become an interesting therapeutic target for metabolic drugs such as metformin (MET). Recently, the administration of the antihypertensive syrosingopine (SYRO) in combination with MET has shown a synergistic effect toward a variety of cancers. However, a fundamental need remains, which is the development of in vivo biomarkers that are able to detect early clinical response...
September 15, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37632970/the-effect-of-metformin-on-triple-negative-breast-cancer-cells-and-nude-mice
#9
JOURNAL ARTICLE
Jin Song, Junfeng Du, Lili Han, Xue Lin, Cibo Fan, Gang Chen
Triple-negative breast cancer (TNBC) presents the most adverse prognosis due to its pronounced invasive and metastatic features. Existing research has highlighted that metformin, a prevalent diabetes medication, possesses strong anti-tumor properties, particularly in inhibiting tumor invasion and metastasis. This study delves deeper into the impact of metformin on TNBC by examining changes in proliferation, apoptosis, invasion, migration, and adhesion of TNBC cells, specifically MDA-MB-231, post-metformin exposure...
August 25, 2023: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/37502330/engineered-vitamin-e-tethered-non-immunogenic-facial-lipopeptide-for-developing-improved-sirna-based-combination-therapy-against-metastatic-breast-cancer
#10
JOURNAL ARTICLE
Argha Mario Mallick, Abhijit Biswas, Sukumar Mishra, Sonali Jadhav, Kasturee Chakraborty, Archana Tripathi, Arnab Mukherjee, Rituparna Sinha Roy
RNA interference based therapeutic gene silencing is an emerging platform for managing highly metastatic breast cancer. Cytosolic delivery of functional siRNA remains the key obstacle for efficient RNAi therapy. To overcome the challenges of siRNA delivery, we have engineered a vitamin E-tethered, short, optimum protease stabilized facial lipopeptide based non-immunogenic, biocompatible siRNA transporter to facilitate the clinical translation in future. Our designed lipopeptide has an Arginine-Sarcosine-Arginine segment for providing optimum protease-stability, minimizing adjacent arginine-arginine repulsion and reducing intermolecular aggregation and α-tocopherol as the lipidic moiety for facilitating cellular permeabilization...
July 26, 2023: Chemical Science
https://read.qxmd.com/read/37473529/metformin-combined-with-glucose-starvation-synergistically-suppress-triple-negative-breast-cancer-by-enhanced-unfolded-protein-response
#11
JOURNAL ARTICLE
Ying Li, Qingqian Zhang, Jintao Yang, Weiping He, Yulan Jiang, Yu Chen, Yifan Wang
Metformin (MET) is a well-documented drug used in the treatment of type II diabetes. Recent studies have revealed its potential anti-tumor effects in various types of cancer. However, the dosage of MET required to exhibit anti-tumor activity is considerably higher than the clinically recommended dosage. In this study, we investigated the synergistical anti-tumor effect of glucose deprivation and MET in MDA-MB-231 cells, which represents a triple-negative breast cancer subtype (TNBC). Our findings demonstrate that glucose deprivation significantly enhances the anti-tumor activity of MET by reducing cell proliferation and increasing cell apoptosis...
July 14, 2023: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/37354381/the-immunomodulatory-effects-of-dexamethasone-on-neoadjuvant-chemotherapy-for-triple-negative-breast-cancer
#12
JOURNAL ARTICLE
Kai Conrad Cecil Johnson, Daniel Goldstein, Jasmin Tharakan, Dionisia Quiroga, Mahmoud Kassem, Michael Grimm, Abdul Miah, Craig Vargo, Michael Berger, Preeti Sudheendra, Ashley Pariser, Margaret E Gatti-Mays, Nicole Williams, Daniel Stover, Sagar Sardesai, Robert Wesolowski, Bhuvaneswari Ramaswamy, Gary Tozbikian, Patrick M Schnell, Mathew A Cherian
INTRODUCTION: The immunomodulatory impact of corticosteroids and concurrent chemotherapy is poorly understood within triple-negative breast cancer (TNBC). On a biochemical level, steroids have been linked to the signaling of chemotherapy-resistant pathways. However, on a clinical level, steroids play an essential role in chemotherapy tolerance through the prevention of chemotherapy-induced nausea and vomiting (CINV) and hypersensitivity reactions. Given these conflicting roles, we wanted to evaluate this interplay more rigorously in the context of early-stage TNBC...
September 2023: Oncology and Therapy
https://read.qxmd.com/read/37225011/combination-therapy-with-pd-1-inhibition-plus-rapamycin-and-metformin-enhances-anti-tumor-efficacy-in-triple-negative-breast-cancer
#13
JOURNAL ARTICLE
Xiaoying Tan, Yan Li, Zhihui Hou, Mingwei Zhang, Li Li, Junmin Wei
Immunotherapy using PD-1/PD-L1 inhibitors has been proved to be effective in triple negative breast cancer (TNBC), albeit only in a fraction of patients. Emerging evidences indicate mTOR blockade and metformin may re-orchestrate the immune system in tumors. Herein, in this study we aimed to evaluate the anti-tumor efficacy of PD-1 monoclonal antibody with mTOR inhibitor rapamycin or with the anti-diabetic drug metformin. The status of PD-1/PD-L1 and mTOR pathway was determined through analyzing the TCGA and CCLE data in TNBCs as well as by detection at mRNA and protein level...
August 1, 2023: Experimental Cell Research
https://read.qxmd.com/read/37224753/metabolic-heterogeneity-in-tnbcs-a-potential-determinant-of-therapeutic-efficacy-of-2-deoxyglucose-and-metformin-combinatory-therapy
#14
JOURNAL ARTICLE
Samson Mathews Samuel, Elizabeth Varghese, Noothan Jyothi Satheesh, Chris R Triggle, Dietrich Büsselberg
Breast cancers (BCs) remain the leading cause of cancer-related deaths among women worldwide. Among the different types of BCs, treating the highly aggressive, invasive, and metastatic triple-negative BCs (TNBCs) that do not respond to hormonal/human epidermal growth factor receptor 2 (HER2) targeted interventions since they lack ER/PR/HER2 receptors remains challenging. While almost all BCs depend on glucose metabolism for their proliferation and survival, studies indicate that TNBCs are highly dependent on glucose metabolism compared to non-TNBC malignancies...
May 22, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37008735/relaxin-encapsulated-polymeric-metformin-nanoparticles-remodel-tumor-immune-microenvironment-by-reducing-cafs-for-efficient-triple-negative-breast-cancer-immunotherapy
#15
JOURNAL ARTICLE
Hongyan Zhang, Liying Chen, Yue Zhao, Ningchao Luo, Jingbin Shi, Shujun Xu, Lisha Ma, Menglin Wang, Mancang Gu, Chaofeng Mu, Yang Xiong
Cancer-associated fibroblasts (CAFs) are one of the most abundant stromal cells in the tumor microenvironment which mediate desmoplastic response and are the primary driver for an immunosuppressive microenvironment, leading to the failure of triple-negative breast cancer (TNBC) immunotherapy. Therefore, depleting CAFs may enhance the effect of immunotherapy (such as PD-L1 antibody). Relaxin (RLN) has been demonstrated to significantly improve transforming growth factor-β (TGF-β) induced CAFs activation and tumor immunosuppressive microenvironment...
March 2023: Asian journal of pharmaceutical sciences
https://read.qxmd.com/read/36656142/yap-taz-axis-was-involved-in-the-effects-of-metformin-on-breast-cancer
#16
JOURNAL ARTICLE
Yu Xu, Hongke Cai, Yuanfeng Xiong, Li Tang, Longjiang Li, Li Zhang, Yi Shen, Yongqiang Yang, Ling Lin, Jiayi Huang
Breast cancer is malignant tumours in women. A large amount of data analysis shows that Metformin has been shown to play a significance role in reducing the risk of breast cancer, but the mechanism remains unclear. The hippo signalling pathway can be involved in the formation, metastasis and recurrence of breast cancer. When YAP/TAZ is activated, cells can overcome contact inhibition and enter a state of uncontrolled proliferation. Therefore, YAP/TAZ is considered a potential therapeutic target for breast cancer...
January 19, 2023: Journal of Chemotherapy
https://read.qxmd.com/read/36482884/metformin-inducing-the-change-of-functional-and-exhausted-phenotypic-tumor-infiltrated-lymphocytes-and-the-correlation-with-jnk-signal-pathway-in-triple-negative-breast-cancer
#17
JOURNAL ARTICLE
Ruibin Wang, Yuchen Li, Yanjie Zhao, Feng Shi, Quan Zhou, Jiangping Wu, Shuzhen Lyu, Qingkun Song
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Metformin has been shown to have the potential to inhibit the proliferation of malignant cells. This study aimed to investigate the regulatory effect of metformin on phenotypic tumor-infiltrated lymphocytes (TILs) and mechanisms in TNBC. METHODS: Microarray analysis was performed on 4T1 cells post metformin treatment. BALB/c mice were inoculated with 4T1 cells with knockdown/overexpression of C-Jun N-terminal kinase (JNK), and administered with metformin...
2022: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/35038549/metformin-inhibits-the-tumor-promoting-effect-of-low-dose-resveratrol-and-enhances-the-anti-tumor-activity-of-high-dose-resveratrol-by-increasing-its-reducibility-in-triple-negative-breast-cancer
#18
JOURNAL ARTICLE
Tingting Cheng, Cheng Wang, Qianqian Lu, Yuru Cao, Weiwei Yu, Wenzhen Li, Ben Liu, Xue Gao, Junhong Lü, Xiaohong Pan
Resveratrol, a natural antioxidant that maintains better bioactivity under hypoxia, has anti-tumor effects, but its underlying mechanism is controversial and the effect on Triple-negative breast cancer (TNBC) remains unclear. Herein, we investigated the anti-TNBC mechanism of resveratrol under a mimic hypoxic tumor microenvironment and explored a method of combining metformin to improve the therapeutic effect. The results showed an inverted "U" shaped relationship between the cell viability and resveratrol concentrations...
February 20, 2022: Free Radical Biology & Medicine
https://read.qxmd.com/read/34741262/enhanced-antiproliferation-potency-of-electrical-pulse-mediated-metformin-and-cisplatin-combination-therapy-on-mda-mb-231-cells
#19
JOURNAL ARTICLE
Praveen Sahu, Ignacio G Camarillo, Raji Sundararajan
We investigated the combined potency of metformin and cisplatin on the MDA-MB-231, triple-negative breast cancer (TNBC) cells with the application of electrical pulses. There are no targeted therapies for this subset of breast cancer because of the absence of specific biomarkers. Cytotoxic chemotherapy is the mainstream mode of treatment for TNBC, and cisplatin is the most commonly used chemotherapeutic drug. While there is a good response initially, TNBC cells develop drug resistance eventually. Thus, there is a need for alternate therapies...
January 2022: Applied Biochemistry and Biotechnology
https://read.qxmd.com/read/34383179/a-randomized-controlled-trial-of-metformin-in-women-with-components-of-metabolic-syndrome-intervention-feasibility-and-effects-on-adiposity-and-breast-density
#20
RANDOMIZED CONTROLLED TRIAL
Edgar Tapia, Diana Evelyn Villa-Guillen, Pavani Chalasani, Sara Centuori, Denise J Roe, Jose Guillen-Rodriguez, Chuan Huang, Jean-Phillippe Galons, Cynthia A Thomson, Maria Altbach, Jesse Trujillo, Liane Pinto, Jessica A Martinez, Amit M Algotar, H-H Sherry Chow
PURPOSE: Obesity is a known risk factor for post-menopausal breast cancer and may increase risk for triple negative breast cancer in premenopausal women. Intervention strategies are clearly needed to reduce obesity-associated breast cancer risk. METHODS: We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention...
November 2021: Breast Cancer Research and Treatment
keyword
keyword
115498
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.